IRAK4 Degraders for Neurological Disorders and Beyond
Legal Citation
Summary of the Inventive Concept
The present inventive concept expands the application of IRAK4 degraders beyond MYD88-mutant B-cell lymphomas to treat neurological disorders, neuroinflammation, neurodegenerative diseases, pain disorders, and psychiatric disorders.
Background and Problem Solved
While IRAK4 degraders have shown promise in treating MYD88-mutant B-cell lymphomas, there remains a significant unmet need for effective treatments of neurological disorders, which are often characterized by inflammation and immune dysregulation. The original patent's IRAK4 degraders were not designed to address these conditions, leaving a gap in the treatment landscape.
Detailed Description of the Inventive Concept
The present inventive concept utilizes IRAK4 degraders, similar to those disclosed in the original patent, but configured to selectively degrade IRAK4 protein and modulate the immune response in the brain. This is achieved through the administration of an IRAK4 degrader, which can be formulated as a composition with a neuroprotective agent, to patients in need thereof. The IRAK4 degrader inhibits IRAK4-mediated inflammation in the central nervous system, reducing symptoms of neurological disorders. Additionally, the IRAK4 degrader can be used to treat pain disorders by inhibiting IRAK4-mediated pain signaling in the nervous system, and psychiatric disorders by modulating the immune response in the brain.
Novelty and Inventive Step
The new claims are novel and non-obvious because they apply the IRAK4 degrader technology to entirely new indications, including neurological disorders, neuroinflammation, neurodegenerative diseases, pain disorders, and psychiatric disorders. The inventive step lies in recognizing the potential of IRAK4 degraders to modulate the immune response in the brain and address these unmet medical needs.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different IRAK4 degraders, formulations, or administration routes. Variations may also include the combination of IRAK4 degraders with other therapeutic agents or modalities to enhance efficacy or reduce side effects.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the treatment of neurological disorders, neuroinflammation, neurodegenerative diseases, pain disorders, and psychiatric disorders. The target market includes pharmaceutical companies, biotechnology companies, and research institutions focused on developing novel therapies for these indications.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically protein degradation technologies and neurological therapeutic interventions, with expertise in immunomodulatory drug design and targeted protein degradation strategies
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in medicinal chemistry or pharmacology, familiar with protein degradation techniques, immunological signaling pathways, and drug repurposing strategies, with knowledge of IRAK4 protein function and therapeutic targeting
Obviousness Rationale
A PHOSITA would recognize that IRAK4 degraders represent a versatile therapeutic platform with potential applications beyond the originally disclosed lymphoma treatment. The fundamental mechanism of IRAK4 protein degradation suggests broader therapeutic potential, particularly in inflammatory and neurological contexts where immune signaling plays a critical role. The technical principles underlying IRAK4 degradation are transferable across different disease states, making the neurological applications a predictable extension of the original technological concept.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,535 |
|---|---|
| Title | Methods of treating mutant lymphomas |
| Assignee(s) | Kymera Therapeutics, Inc. |